MUMBAI, India, July 30, 2026 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the First Quarter (Q1) ended 30th June 2026. EBITDA Margin : EBITDA increased by 72%, with EBITDA margin expanding by approximately 400 basis points to 12.5%, reflecting improved operating leverage and execution. Improved Operating Performance: Higher capacity utilization, operating leverage, pricing discipline and operational excellence supported EBITDA margin expansion. Nandini Piramal, Chairperson, Piramal Pharma Limited said, “We have started FY27 on a strong note, with all three businesses delivering mid-to-high teens revenue growth alongside meaningful EBITDA margin expansion. For more information, visit: Piramal Pharma | LinkedIn1Includes one facility via PPL’s minority investment in Yapan Bio.